Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance study of aldesleukin and zoledronic acid after autologous transplant in multiple myeloma
2009-012583-13Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Sep 2009
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin and zoledronic acid in multiple myeloma (MM), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Disease progression. Started Sep 2009; status: active.
02
Drugs
aldesleukinzoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-012583-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012583-13.